- Home
- TDF vs CRBP Comparison
TDF vs CRBP Comparison
Compare TDF & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDF
- CRBP
- Stock Information
- Founded
- TDF 1994
- CRBP 2009
- Country
- TDF Singapore
- CRBP United States
- Employees
- TDF N/A
- CRBP N/A
- Industry
- TDF Finance/Investors Services
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- TDF Finance
- CRBP Health Care
- Exchange
- TDF Nasdaq
- CRBP Nasdaq
- Market Cap
- TDF 244.7M
- CRBP 233.5M
- IPO Year
- TDF N/A
- CRBP N/A
- Fundamental
- Price
- TDF $11.49
- CRBP $11.05
- Analyst Decision
- TDF
- CRBP Strong Buy
- Analyst Count
- TDF 0
- CRBP 9
- Target Price
- TDF N/A
- CRBP $48.38
- AVG Volume (30 Days)
- TDF 79.2K
- CRBP 637.3K
- Earning Date
- TDF 01-01-0001
- CRBP 11-12-2025
- Dividend Yield
- TDF N/A
- CRBP N/A
- EPS Growth
- TDF N/A
- CRBP N/A
- EPS
- TDF N/A
- CRBP N/A
- Revenue
- TDF N/A
- CRBP N/A
- Revenue This Year
- TDF N/A
- CRBP N/A
- Revenue Next Year
- TDF N/A
- CRBP $220.00
- P/E Ratio
- TDF N/A
- CRBP N/A
- Revenue Growth
- TDF N/A
- CRBP N/A
- 52 Week Low
- TDF $7.15
- CRBP $4.64
- 52 Week High
- TDF $10.62
- CRBP $20.56
- Technical
- Relative Strength Index (RSI)
- TDF 47.34
- CRBP 35.70
- Support Level
- TDF $11.34
- CRBP $10.20
- Resistance Level
- TDF $11.86
- CRBP $11.50
- Average True Range (ATR)
- TDF 0.29
- CRBP 0.93
- MACD
- TDF -0.00
- CRBP -0.44
- Stochastic Oscillator
- TDF 54.94
- CRBP 14.67
About TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.